Richard Bucala

TL;DR: It is shown that naive B and T cells interact via the signaling lymphocyte activation molecule (SLAM) family receptor, SLAMF6, which results in an upregulation of the expression of the cytokine migration inhibitory factor in the T cells and augmented expression of its receptor CD74 on the B cell counterparts, consequently enhancing B cell survival.

TL;DR: The D-DT (MIF-2) interaction with CD74 is studied that is mainly defined by three elements scattered throughout the disordered regions of the interacting molecules, which has implications for the manner in which D- DT and MIF compete with each other for binding to the CD74 receptor and for the relative potency of DRa1-MOG-35-55 and RTL1000 for competitive inhibition of D-dopachrome tautomerase.

TL;DR: D-DT and its receptor are expressed in the murine tumors B16F10 and 4T1 and knock-down of D-DT through siRNA or blocking by antibodies reduced proliferation of B 16F10 tumor cells, qualifying D- DT for further evaluation as a therapeutic target.

TL;DR: Ex vivo endogenous cardiomyocyte DDT has pleiotropic actions that are protective against heart failure.

TL;DR: 4-(3-Carboxyphenyl)-2,5-pyridinedicarboxylic acid (4-CPPC) is reported as the first reversible and selective small molecule inhibitor of pro-inflammatory protein macrophage migration inhibitory factor-2 (also known as MIF-2 or d-DT).